Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: a single-center preliminary experience.

MLA

Leanza, Cristiana, et al. “Real-World Use of Imipenem/Cilastatin/Relebactam for the Treatment of KPC-Producing Klebsiella Pneumoniae Complex and Difficult-to-Treat Resistance (DTR) Pseudomonas Aeruginosa Infections: A Single-Center Preliminary Experience.” Frontiers in Microbiology, vol. 15, July 2024, p. 1432296. EBSCOhost, https://doi.org/10.3389/fmicb.2024.1432296.

APA

Leanza, C., Mascellino, M. T., Volpicelli, L., Covino, S., Falletta, A., Cancelli, F., Franchi, C., Carnevalini, M., Mastroianni, C. M., & Oliva, A. (2024). Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: a single-center preliminary experience. Frontiers in Microbiology, 15, 1432296. https://doi.org/10.3389/fmicb.2024.1432296

Chicago

Leanza, Cristiana, Maria Teresa Mascellino, Lorenzo Volpicelli, Sara Covino, Antonio Falletta, Francesca Cancelli, Cristiana Franchi, Martina Carnevalini, Claudio M Mastroianni, and Alessandra Oliva. 2024. “Real-World Use of Imipenem/Cilastatin/Relebactam for the Treatment of KPC-Producing Klebsiella Pneumoniae Complex and Difficult-to-Treat Resistance (DTR) Pseudomonas Aeruginosa Infections: A Single-Center Preliminary Experience.” Frontiers in Microbiology 15 (July): 1432296. doi:10.3389/fmicb.2024.1432296.